These Analysts Cut Their Forecasts On Elevance Health Following Q3 Earnings
These Analysts Cut Their Forecasts On Elevance Health Following Q3 Earnings
Elevance Health expects GAAP net income per diluted share of approximately $26.50 versus the prior guidance of at least $34.05. The company forecasts an adjusted EPS of $33.00, down from the prior guidance of at least $37.20 and the consensus of $37.26.Elevance Health Inc. (NYSE:ELV) reported weaker-than-expected earnings for its third quarter on Thursday.
Elevance Health Inc.（紐交所:ELV）週四報告稱，其第三季度盈利低於預期。
The company posted revenues of $44.7 billion, up 5.3% year-over-year, beating the consensus of $43.33 billion. Profit fell 21% to $1.02 billion, or $4.36 a share. Per-share adjusted earnings reached $8.37, down from $8.99 a year ago, missing the consensus of $9.66.
該公司收入爲447億美元，同比增長5.3%，超出預期的433.3億美元。利潤下降21%至10.2億美元，每股收益爲4.36美元。每股調整後收益爲8.37美元，低於去年的8.99美元，未達到預期的9.66美元。
"We remain confident in the long-term earnings potential of our diverse businesses as we navigate a dynamic operating environment and unprecedented challenges in the Medicaid business. We expect Medicaid rates will align with the needs of our members in time, and are taking proactive actions to enhance operational efficiencies that will ensure we emerge from this period even stronger," said Gail Boudreaux, President & CEO.
「我們對我們多樣化業務的長期盈利潛力充滿信心，因爲我們在應對一個充滿變數的運營環境和醫療保險業務中前所未有的挑戰。我們預計醫療保險費率將與我們會員的需求相匹配，同時我們正在積極採取行動，提高運營效率，以確保我們在這一時期變得更加強大，」 Gail Boudreaux，總裁兼首席執行官表示。
Elevance Health expects GAAP net income per diluted share of approximately $26.50 versus the prior guidance of at least $34.05. The company forecasts an adjusted EPS of $33.00, down from the prior guidance of at least $37.20 and the consensus of $37.26.
Elevance Health預計每股攤薄淨利潤約爲26.50美元，低於此前至少爲34.05美元的指引。公司預測調整後的每股收益爲33.00美元，低於此前至少爲37.20美元的指引以及37.26美元的共識。
Elevance Health shares fell 3.4% to trade at $429.30 on Friday.
Elevance Health股價週五下跌3.4%，報429.30美元。
These analysts made changes to their price targets on Blackstone following earnings announcement.
這些分析師根據收益公告調整了對黑石的價格目標。
- Cantor Fitzgerald analyst Sarah James maintained Elevance Health with an Overweight and lowered the price target from $600 to $485.
- RBC Capital analyst Ben Hendrix maintained the stock with an Outperform and lowered the price target from $585 to $478.
- Truist Securities analyst David Macdonald reiterated Elevance Health with a Buy and lowered the price target from $620 to $520.
- UBS analyst A.J. Rice maintained Elevance Health with a Buy and lowered the price target from $605 to $555.
- Cantor Fitzgerald分析師Sarah James維持對Elevance Health的超配評級，將價格目標從600美元下調至485美元。
- RBC Capital分析師Ben Hendrix維持該股票的表現評級，將價格目標從585美元下調至478美元。
- Truist Securities 分析師 David Macdonald 重申買入 Elevance Health，將價格目標從$620降至$520。
- UBS 分析師 A.J. Rice 維持買入 Elevance Health，並將價格目標從$605降至$555。
Considering buying ELV stock? Here's what analysts think:
考慮買入 ELV 股票嗎？這是分析師的看法：
譯文內容由第三人軟體翻譯。
